Verona Pharma Inc. (VRNA) - מקדם חוב לטווח ארוך להון

The development of Verona Pharma plc (VRNA) relies on the market launch of the innovative COPD treatment Ohtuvayre and the prospects of merging with industry behemoths. The price action for the separate_debt_long_eq metric is 0.81, which coincides with risks of supply chain disruptions and the complexities of patent protection amid global instability. Currently, the fate of the business depends on the sales effectiveness of the new pulmonary product and the performance of distributors.

This indicator assesses financial leverage by determining the proportion of long-term liabilities relative to equity to analyze the business's solvency. The trend of the ratio of loans exceeding one year to equity demonstrates the degree of Verona Pharma plc (VRNA) dependence on external financing, which is critical given the unpredictable cash flows during the market launch of its primary drug.